卵巢癌肿瘤标志物研究进展

卵巢癌是妇科三大恶性肿瘤之一,由于疾病早期没有明显的临床症状,发现时多已进展为晚期,且约80%的晚期患者在治疗后3年内复发,因此卵巢癌成为妇科恶性肿瘤中死亡率最高的肿瘤。早期有效的筛查及预后评估机制对卵巢癌的诊断及治疗有重要意义。CA125是监测卵巢癌病程和转归的重要标志物,然而其特异性不足,其他标志物包括HE4、CA199对卵巢癌的诊断和预后也缺乏敏感性和特异性。因此,寻找和鉴定新的分子标志物用于早期筛查和诊断卵巢癌以及评估预后至关重要。本文基于目前卵巢癌生物标志物最新研究进行综述。

Research progress on tumor markers of ovarian cancer

Ovarian cancer is one of the three major malignant tumors in gynecology,because there are no obvious clinical symptoms in the early stage of the disease,it has progressed to advanced stage when it is found,and about 80%of advanced patients will relapse within 3 years after treatment,so ovarian cancer has become the tumor with the highest mortality rate in gynecological malignant tumors.Early and effective screening and assessment of prognostic mechanisms will be of great significance for the diagnosis and treatment of ovarian cancer.CA125 is a well-known marker for monitoring the course and outcome of ovarian cancer.However,its specificity is insufficient.Other markers,including HE4 and CA199,also lack sensitivity and specificity for the diagnosis and prognosis of ovarian cancer.Therefore,it is crucial to find and identify new molecular markers for early screening and diagnosis of ovarian cancer,as well as to assess prognosis.This review highlights current biomarkers of specific diagnosis and prognosis of ovarian cancer based on the latest evidence.